AU716282B2
(en)
|
1995-06-07 |
2000-02-24 |
Johnson & Johnson Research Pty. Limited |
CDR-grafted anti-tissue factor antibodies and methods of use thereof
|
US6703197B1
(en)
*
|
1996-11-27 |
2004-03-09 |
Martinex R&D, Inc. |
Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
|
US7749498B2
(en)
*
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20030109680A1
(en)
*
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US5986065A
(en)
*
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20060235209A9
(en)
*
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
US7764130B2
(en)
*
|
1999-01-22 |
2010-07-27 |
Multigig Inc. |
Electronic circuitry
|
AU7450600A
(en)
*
|
1999-10-01 |
2001-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
DE19962583A1
(de)
*
|
1999-12-23 |
2001-06-28 |
Mueller Hermelink Hans Konrad |
Antikörper gegen Plasmazellen
|
JP2003527861A
(ja)
*
|
2000-03-16 |
2003-09-24 |
ジェネンテック・インコーポレーテッド |
増強した抗血液凝固能を持つ抗組織因子抗体
|
US6703494B2
(en)
|
2000-03-16 |
2004-03-09 |
Genentech, Inc. |
Anti-tissue factor antibodies with enhanced anticoagulant potency
|
US8632778B2
(en)
|
2000-08-11 |
2014-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized anti-interleukin-6 antibody-containing preparations
|
EP3088412B1
(fr)
|
2001-03-09 |
2021-05-05 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé de purification de protéines
|
WO2002078738A1
(fr)
*
|
2001-03-26 |
2002-10-10 |
Koji Suzuki |
Agents ameliorant la rheologie sanguine
|
EP1428537B1
(fr)
*
|
2001-08-29 |
2008-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
Preparations stabilisees contenant un anticorps
|
JP2005512970A
(ja)
*
|
2001-10-02 |
2005-05-12 |
ノボ ノルディスク アクティーゼルスカブ |
ヒト組織因子抗体
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
EP1464702A4
(fr)
|
2001-12-28 |
2005-09-21 |
Chugai Pharmaceutical Co Ltd |
Procede de stabilisation d'une proteine
|
MXPA04010851A
(es)
*
|
2002-05-01 |
2005-02-14 |
Schering Ag |
Proteinas de fusion de trombomodulina dirigidas al factor tisular novedoso como anticoagulantes.
|
GB0210783D0
(en)
*
|
2002-05-10 |
2002-06-19 |
Polonelli Luciano |
Anti-microbial polypeptides
|
WO2003099324A1
(fr)
*
|
2002-05-23 |
2003-12-04 |
Chugai Seiyaku Kabushiki Kaisha |
Agent neutralisant l'inhibiteur du facteur tissulaire et agent neutralisant la preparation du facteur viii active de coagulation sanguine
|
WO2004019966A1
(fr)
|
2002-08-27 |
2004-03-11 |
Chugai Seiyaku Kabushiki Kaisha |
Methode de stabilisation de preparations de solution de proteines
|
KR101119448B1
(ko)
|
2002-09-11 |
2012-03-15 |
추가이 세이야쿠 가부시키가이샤 |
단백질 정제 방법
|
AU2003277832A1
(en)
*
|
2002-10-31 |
2004-05-25 |
Novo Nordisk A/S |
Humanized tissue factor antibodies
|
EP1608684A2
(fr)
*
|
2003-02-07 |
2005-12-28 |
Protein Design Labs, Inc. |
Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis
|
AU2004216298B2
(en)
*
|
2003-02-28 |
2009-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized protein-containing formulations
|
US7425328B2
(en)
*
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
CA2527621A1
(fr)
*
|
2003-05-30 |
2004-12-23 |
Centocor, Inc. |
Procede pour inhiber la croissance tumorale avec des anticorps a facteurs anti-tissulaires
|
CN1863556B
(zh)
*
|
2003-06-19 |
2012-05-16 |
吉宁特有限公司 |
用于治疗凝血相关紊乱的组合物和方法
|
AU2004268648A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Centocor, Inc. |
Method of promoting graft survival with anti-tissue factor antibodies
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
JPWO2005035754A1
(ja)
|
2003-10-14 |
2006-12-21 |
中外製薬株式会社 |
機能蛋白質を代替する二種特異性抗体
|
US9296820B2
(en)
*
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
CA2582683A1
(fr)
|
2004-10-01 |
2006-04-13 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Nouveaux anticorps diriges contre la proteine de canal ionique eag1 mammifere
|
EP1676574A3
(fr)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Procédé favorisant la survie des tissus ou cellules griffées
|
JP2008533985A
(ja)
*
|
2005-03-25 |
2008-08-28 |
グリクアート バイオテクノロジー アクチェンゲゼルシャフト |
MCSPを対象とし、且つ、Fc受容体結合親和性とエフェクター機能を増強した抗原結合分子
|
EP3050963B1
(fr)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
|
DK2824183T3
(da)
|
2005-04-08 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af bispecifikke antistoffer
|
CN101228189A
(zh)
*
|
2005-05-09 |
2008-07-23 |
格黎卡特生物技术股份公司 |
具有修饰的fc区域和改变的与fc受体的结合的抗原结合分子
|
CA2619725C
(fr)
|
2005-08-18 |
2016-06-07 |
Ramot At Tel Aviv University Ltd. |
Anticorps monocatenaires diriges contre le peptide beta-amyloide
|
AR055137A1
(es)
*
|
2005-08-26 |
2007-08-08 |
Glycart Biotechnology Ag |
Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
|
EP1977763A4
(fr)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Préparation stabilisatrice contenant des anticorps
|
EP3345616A1
(fr)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé de modification d'anticorps pour purifier un anticorps bispécifique
|
IN2014DN10515A
(fr)
*
|
2006-03-31 |
2015-08-21 |
Chugai Pharmaceutical Co Ltd |
|
US20090285819A1
(en)
*
|
2006-11-15 |
2009-11-19 |
Functional Genetics, Inc. |
Methods and compositions for treating influenza
|
FR2909092B1
(fr)
*
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
Nouveaux anticorps anti-proliferation
|
SI2662091T1
(sl)
|
2006-12-01 |
2019-01-31 |
Novartis Ag |
Protitelesa proti P-selektinu in postopki za njihovo uporabo za zdravljenje vnetnih bolezni
|
PL3059246T3
(pl)
|
2007-09-26 |
2018-11-30 |
Chugai Seiyaku Kabushiki Kaisha |
Zmodyfikowany region stały przeciwciała
|
CA2700701C
(fr)
|
2007-09-26 |
2020-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procede permettant de modifier le point isoelectrique d'un anticorps par substitution d'acide amine dans une region determinant la complementarite (cdr)
|
ES2834741T3
(es)
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-NR10 y uso del mismo
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
BR122012027456A2
(pt)
*
|
2008-03-14 |
2015-07-14 |
Allergan Inc |
Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a
|
CA2721093A1
(fr)
|
2008-04-11 |
2009-10-15 |
Merrimack Pharmaceuticals, Inc. |
Lieurs d'albumine de serum humain, et ses conjugues
|
US8187601B2
(en)
*
|
2008-07-01 |
2012-05-29 |
Aveo Pharmaceuticals, Inc. |
Fibroblast growth factor receptor 3 (FGFR3) binding proteins
|
CN102089004B
(zh)
|
2008-07-10 |
2018-06-01 |
东丽株式会社 |
癌的治疗及预防用药物组合物
|
DK2322221T3
(da)
|
2008-08-05 |
2014-09-01 |
Toray Industries |
Farmaceutisk sammensætning til behandling og forebyggelse af cancer
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
CN102282168A
(zh)
*
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
EP2380976A4
(fr)
|
2008-12-25 |
2012-11-07 |
Univ Osaka |
Anticorps humain anti-virus de la grippe humaine
|
EP2409991B1
(fr)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Variant d'une région constante d'anticorps
|
TWI646193B
(zh)
|
2009-03-19 |
2019-01-01 |
中外製藥股份有限公司 |
抗體恆定區域改變體
|
CN102459344A
(zh)
|
2009-05-15 |
2012-05-16 |
中外制药株式会社 |
抗axl抗体
|
US20120141501A1
(en)
|
2009-05-29 |
2012-06-07 |
Forerunner Pharma Research Co. Ltd |
Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
|
WO2011037158A1
(fr)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
Régions constantes modifiées d'un anticorps
|
CN101717447B
(zh)
*
|
2009-12-17 |
2012-06-27 |
山西省生物研究所 |
一种抗人重组组织因子单克隆抗体的制备方法
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
CA2788715C
(fr)
|
2010-02-04 |
2021-06-08 |
Toray Industries, Inc. |
Composition pharmaceutique pour le traitement et/ou la prevention du cancer
|
DK2532364T3
(en)
|
2010-02-04 |
2016-08-15 |
Toray Industries |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER
|
US8937160B2
(en)
|
2010-02-04 |
2015-01-20 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
RU2567657C2
(ru)
|
2010-02-04 |
2015-11-10 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
WO2011096534A1
(fr)
|
2010-02-04 |
2011-08-11 |
東レ株式会社 |
Composition pharmaceutique pour le traitement et/ou la prévention du cancer
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
EP2582728B1
(fr)
|
2010-06-15 |
2017-08-23 |
Genmab A/S |
Conjugués anticorps humain-médicament contre le facteur tissulaire
|
RS57038B1
(sr)
|
2010-11-17 |
2018-05-31 |
Chugai Pharmaceutical Co Ltd |
Multi-specifičan antigen-vezujući molekul koji ima alternativnu funkciju funkciji faktora viii koagulacije krvi
|
SG192945A1
(en)
|
2011-02-25 |
2013-09-30 |
Chugai Pharmaceutical Co Ltd |
Fcgriib-specific fc antibody
|
US8722044B2
(en)
|
2011-03-15 |
2014-05-13 |
Janssen Biotech, Inc. |
Human tissue factor antibody and uses thereof
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
KR101968499B1
(ko)
|
2011-08-04 |
2019-04-12 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
ES2609859T3
(es)
|
2011-08-04 |
2017-04-24 |
Toray Industries, Inc. |
Composición de fármaco para el tratamiento y/o la prevención del cáncer
|
RU2610428C2
(ru)
|
2011-08-04 |
2017-02-10 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
|
MX359235B
(es)
|
2011-09-01 |
2018-09-20 |
Chugai Pharmaceutical Co Ltd |
Metodo para preparar una composicion que comprende anticuerpos altamente concentrados por ultrafiltracion.
|
EP3939996A1
(fr)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
ES2739380T3
(es)
|
2012-02-21 |
2020-01-30 |
Toray Industries |
Composición farmacéutica para el tratamiento del cáncer
|
PT2818482T
(pt)
|
2012-02-21 |
2019-08-06 |
Toray Industries |
Composição farmacêutica para o tratamento de cancro
|
WO2013125630A1
(fr)
|
2012-02-21 |
2013-08-29 |
東レ株式会社 |
Composition pharmaceutique pour le traitement et/ou la prévention du cancer
|
IN2014KN01715A
(fr)
|
2012-02-21 |
2015-10-23 |
Toray Industries |
|
RU2640245C2
(ru)
|
2012-03-30 |
2017-12-27 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или предотвращения рака печени
|
JP6107655B2
(ja)
|
2012-03-30 |
2017-04-05 |
東レ株式会社 |
胆嚢癌の治療及び/又は予防用医薬組成物
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
WO2014036520A1
(fr)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Polythérapies comprenant des agents anti-erbb3
|
CA2886326C
(fr)
|
2012-09-28 |
2021-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
Procede d'evaluation de reaction de coagulation du sang
|
HUE042081T2
(hu)
|
2013-08-09 |
2019-06-28 |
Toray Industries |
Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
|
SG10201803449VA
(en)
|
2013-09-27 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
JP6722455B2
(ja)
|
2013-12-27 |
2020-07-15 |
中外製薬株式会社 |
等電点の低い抗体の精製方法
|
US10538591B2
(en)
|
2014-03-10 |
2020-01-21 |
The Brigham And Women's Hospital, Inc. |
Anti-fibulin-3 antibodies and uses thereof
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
EP4056993A1
(fr)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé de mesure de viscosité d'une solution de protéine
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
WO2016065245A1
(fr)
|
2014-10-24 |
2016-04-28 |
Incept, Llc |
Échafaudage extraluminal
|
EP3209769B1
(fr)
|
2014-10-24 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions et procédés pour induire la phagocytose de cellules positives de classe i du cmh et pour contrer la résistance aux agents anti-cd47/sirpa
|
US9765135B2
(en)
|
2014-12-19 |
2017-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies
|
CR20170326A
(es)
|
2014-12-19 |
2017-08-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
|
WO2016125495A1
(fr)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations
|
WO2016136933A1
(fr)
|
2015-02-27 |
2016-09-01 |
中外製薬株式会社 |
Composition pour le traitement de maladies associées à il-6
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
AU2016248817A1
(en)
|
2015-04-17 |
2017-08-17 |
F. Hoffmann-La Roche Ag |
Combination therapy with coagulation factors and multispecific antibodies
|
CA3004830A1
(fr)
|
2015-11-11 |
2017-05-18 |
Opi Vi- Ip Holdco Llc |
Composition et methodes pour anticorps anti-tnfr2
|
EP3395835B1
(fr)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps présentant une activité accrue et son procédé de modification
|
WO2017110981A1
(fr)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps anti-myostatine et procédés d'utilisation
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
WO2017159287A1
(fr)
|
2016-03-14 |
2017-09-21 |
中外製薬株式会社 |
Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer
|
JP6939555B2
(ja)
|
2016-03-28 |
2021-09-22 |
東レ株式会社 |
癌の治療及び/又は予防用医薬組成物
|
CA3029003A1
(fr)
|
2016-06-27 |
2018-01-04 |
The Regents Of The University Of California |
Associations medicamenteuses pour le traitement du cancer
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
US20200054762A1
(en)
|
2016-10-28 |
2020-02-20 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
TW201836636A
(zh)
|
2017-03-31 |
2018-10-16 |
公立大學法人奈良縣立醫科大學 |
含有替代凝血因子viii功能之多特異性抗原結合分子之用於預防和/或治療凝血因子ix異常症的醫藥組合物
|
US20200109390A1
(en)
|
2017-04-27 |
2020-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
Coagulation factor ix with improved pharmacokinetics
|
EP3620531A4
(fr)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
|
TW201922796A
(zh)
*
|
2017-10-30 |
2019-06-16 |
國立研究開發法人國立癌症研究中心 |
可用於實體腫瘤治療之抗體及其抗體-藥物共軛物以及含其之抗癌劑
|
CA3083345A1
(fr)
*
|
2017-11-27 |
2019-05-31 |
Purdue Pharma L.P. |
Anticorps humanises ciblant le facteur tissulaire humain
|
CA3087537A1
(fr)
|
2018-01-04 |
2019-07-11 |
Jan-willem THEUNISSEN |
Anticorps anti-facteur tissulaire, conjugues anticorps-medicament et procedes associes
|
BR112020019935A2
(pt)
|
2018-03-30 |
2021-01-26 |
Toray Industries, Inc. |
medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer
|
WO2019225568A1
(fr)
|
2018-05-21 |
2019-11-28 |
中外製薬株式会社 |
Formulation lyophilisée scellée dans un flacon en verre
|
US11708186B2
(en)
|
2018-05-28 |
2023-07-25 |
Chugai Seiyaku Kabushiki Kaisha |
Filling nozzle
|
AU2020258025A1
(en)
|
2019-04-18 |
2021-11-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
WO2021110995A1
(fr)
|
2019-12-04 |
2021-06-10 |
Ac Immune Sa |
Nouvelles molécules de thérapie et de diagnostic
|
KR20220152309A
(ko)
|
2020-03-12 |
2022-11-15 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
KR20220151684A
(ko)
|
2020-03-12 |
2022-11-15 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
KR20220152318A
(ko)
|
2020-03-12 |
2022-11-15 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
BR112022018171A2
(pt)
|
2020-03-12 |
2022-10-25 |
Toray Industries |
Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
|
WO2021182570A1
(fr)
|
2020-03-12 |
2021-09-16 |
東レ株式会社 |
Médicament pour le traitement et/ou la prévention du cancer
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
TW202144429A
(zh)
|
2020-05-14 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗cd25抗體、其抗原結合片段及其醫藥用途
|
US20230183376A1
(en)
|
2020-05-22 |
2023-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
|
EP4229082A1
(fr)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Anticorps se liant à l'alpha-synucléine à usage thérapeutique et diagnostique
|
IL303758A
(en)
|
2020-12-18 |
2023-08-01 |
Ac Immune Sa |
Antibody transport
|
CN117460532A
(zh)
|
2021-06-23 |
2024-01-26 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
BR112023026985A2
(pt)
|
2021-06-23 |
2024-03-12 |
Toray Industries |
Medicamento para o tratamento e/ou prevenção do câncer, agente que aumenta a eficácia do medicamento em uma composição farmacêutica, agente para aumentar a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
|
CN117693363A
(zh)
|
2021-07-27 |
2024-03-12 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
AU2022316644A1
(en)
|
2021-07-27 |
2024-02-29 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
CA3227706A1
(fr)
|
2021-07-27 |
2023-02-02 |
Toray Industries, Inc. |
Medicament pour le traitement et/ou la prevention du cancer
|
WO2023033129A1
(fr)
|
2021-09-03 |
2023-03-09 |
東レ株式会社 |
Composition pharmaceutique pour le traitement et/ou la prévention du cancer
|
TW202333781A
(zh)
|
2021-10-08 |
2023-09-01 |
日商中外製藥股份有限公司 |
抗hla-dq2﹒5抗體製劑
|